An evolutionary approach to restoring health
AOBiome Therapeutics is a clinical-stage therapeutics company addressing a broad range of inflammatory conditions by harnessing a single strain of class defining
Ammonia Oxidizing Bacteria (AOB).
The Bio-inflammation Company
Transforming Human Health Through The Restoration Of Ammonia-Oxidizing BacteriaAOBiome currently has multiple
Phase 2 clinical programs ongoing
AOBiome currently has ongoing Phase 2 clinical programs in hypertension, acne, allergic rhinitis, migraine, eczema and rosacea.
Committed to transforming & improving human health
We believe that the restoration of the symbiotic relationship between bacteria and humans
will have a profound impact on human health.
In the News
June 4, 2018
· Cambridge, MA
AOBiome Therapeutics Announces Election of Dr. Jun Wang as Chairman of the Board of Directors
April 23, 2018
· Cambridge, MA
AOBiome Therapeutics Expands Clinical-Stage Pipeline, Initiates Phase 2 Clinical Trial for Episodic Migraine
March 21, 2018
· Cambridge, MA
AOBiome Therapeutics Reports Positive Clinical Safety Results for First-in-Class Microbiome-Targeted Therapy for Intranasal Delivery